Business
Axsome is a CNS biopharma company with FDA-approved medicines for major depressive disorder, excessive daytime sleepiness, and migraine.
Axsome revenue surged on CNS products, losses narrowed, cash burn improved, and insider activity was still sales-heavy.
The read at a glance✓ Audited against SEC data
- Business mix — CNS medicines: AUVELITY, SUNOSI, SYMBRAVONote
- Revenue — Revenue rose 65.5%OK
- Losses — Net loss narrowed to $183.2MOK
- Cash — Free cash flow improved to -$93.9MOK
- Balance sheet — Debt fell; equity rose 54.9%OK
- Insiders — 1 buy / 33 sellsWatch
- Accounting — Altman-Z distress; other screens safeWatch
Where the revenue comes from
Fiscal 2025, as Axsome Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Product$633.8M
- Royalty And Milestone Revenue$4.7M
Leadership changes
From Axsome Therapeutics, Inc.'s own filings, the day they're filed.
- Susan Mahony · director · appointmenteff. 2023-10-10
- Involuntary Termination · vice president · departure
- Control Period · departure
Latest filings
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-09
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Axsome Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.